For 12 years, the FDA and the Drug Enforcement Administration have been studying whether to move medicines containing hydrocodone from the Schedule III category to the more restrictive Schedule II.
ED visits related to use of non-medical hydrocodone rose from 19,221 in 2000 to 86,258 in 2009.
Related Articles on Hydrocodone:
Utah Orthopedic Surgeon Defends Use of Pain Meds During Trial
Drugmakers Recall Certain Oxycodone, Hydrocodone Pills
Boca Pharmacal Receives FDA Approval of Generic Drug for Pain
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
